Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/201061
Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Purpose: Tumor antigens are central to antitumor immunity. Recent evidence suggests that peptides from noncanonical (nonC) aberrantly translated proteins can be presented on HLA-I by tumor cells. Here, we investigated the immunogenicity of nonC tumor HLA-I ligands (nonC-TL) to better understand their contribution to cancer immunosurveillance and their therapeutic applicability. Experimental Design: Peptides presented on HLA-I were iden-tified in 9 patient-derived tumor cell lines from melanoma, gyneco-logic, and head and neck cancer through proteogenomics. A total of 507 candidate tumor antigens, including nonC-TL, neoantigens, cancer-germline, or melanocyte differentiation antigens, were tested for T-cell recognition of preexisting responses in patients with cancer. Donor peripheral blood lymphocytes (PBL) were in vitro sensitized against 170 selected nonC-TL to isolate antigen-specific T-cell recep-tors (TCR) and evaluate their therapeutic potential.Rudolf Virchow Center, Center for Integrative and Transla- tional Bioimaging, Julius-Maximilians-University Wueurorzburg, Wueurorzburg, Germany
Matèries
Matèries (anglès)
Citació
Citació
LOZANO RABELLA, Maria, GARCIA GARIJO, Andrea, PALOMERO, Jara, YUSTE ESTEVANEZ, Anna, ERHARD, Florian, FARRIOL DURAN, Roc, MARTÍN LIBERAL, Juan, OCHOA DE OLZA, Maria, MATOS, Ignacio, GARTNER, Jared j., GHOSH, Michael, CANALS, Francesc, VIDAL, August, PIULATS, Josep m., MATIAS-GUIU, Xavier, BRANA, Irene, MUÑOZ COUSELO, Eva, GARRALDA, Elena, SCHLOSSER, Andreas, GROS VIDAL, Alena. Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics. _Clinical Cancer Research_. 2023. Vol. 29, núm. 12, pàgs. 2250-2265. [consulta: 21 de gener de 2026]. ISSN: 1557-3265. [Disponible a: https://hdl.handle.net/2445/201061]